These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 30362320)

  • 41. Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST).
    Daniels M; Lurkin I; Pauli R; Erbstösser E; Hildebrandt U; Hellwig K; Zschille U; Lüders P; Krüger G; Knolle J; Stengel B; Prall F; Hertel K; Lobeck H; Popp B; Theissig F; Wünsch P; Zwarthoff E; Agaimy A; Schneider-Stock R
    Cancer Lett; 2011 Dec; 312(1):43-54. PubMed ID: 21906875
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mutations of the
    Wang S; Zhang Q; Wu H; Yang Z; Guo X; Wang F; Yu Z; Zhong Z
    Niger J Clin Pract; 2021 Jun; 24(6):814-820. PubMed ID: 34121727
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic relevance of KIT and PDGFRA mutations in gastrointestinal stromal tumors.
    Braggio E; Braggio Dde A; Small IA; Lopes LF; Valadão M; Gouveia ME; Moreira Ados S; Linhares E; Romano S; Bacchi CE; Renault IZ; Guimarães DP; Ferreira CG
    Anticancer Res; 2010 Jun; 30(6):2407-14. PubMed ID: 20651400
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Detection of c-KIT and PDGFRA gene mutations in gastrointestinal stromal tumors: comparison of DHPLC and DNA sequencing methods using a single population-based cohort.
    Battochio A; Mohammed S; Winthrop D; Lefresne S; Mulder K; Chu Q; O'Hara C; Lai R
    Am J Clin Pathol; 2010 Jan; 133(1):149-55. PubMed ID: 20023271
    [TBL] [Abstract][Full Text] [Related]  

  • 45. C-KIT and PDGFRA zygosity in gastrointestinal stromal tumors: Correlation with tumor site, tumor size, exon, and CD117 immunohistochemistry.
    Wallander ML; Willmore-Payne C; Layfield LJ
    Appl Immunohistochem Mol Morphol; 2011 Jan; 19(1):21-7. PubMed ID: 20823768
    [TBL] [Abstract][Full Text] [Related]  

  • 46. KIT and PDGFRa mutational patterns in Sardinian patients with gastrointestinal stromal tumors.
    Palomba G; Paliogiannis P; Sini MC; Colombino M; Casula M; Manca A; Pisano M; Sotgiu G; Doneddu V; Palmieri G; Cossu A
    Eur J Cancer Prev; 2021 Jan; 30(1):53-58. PubMed ID: 32091431
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Epithelioid gastrointestinal stromal tumor with PDGFRA activating mutation and immunoreactivity.
    Yi ES; Strong CR; Piao Z; Perucho M; Weidner N
    Appl Immunohistochem Mol Morphol; 2005 Jun; 13(2):157-61. PubMed ID: 15894928
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Gastrointestinal stromal tumors (GIST): at the forefront of targeted therapies].
    Emile JF
    Med Sci (Paris); 2013; 29(6-7):630-6. PubMed ID: 23859518
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression profiling of GIST: CD133 is associated with KIT exon 11 mutations, gastric location and poor prognosis.
    Arne G; Kristiansson E; Nerman O; Kindblom LG; Ahlman H; Nilsson B; Nilsson O
    Int J Cancer; 2011 Sep; 129(5):1149-61. PubMed ID: 21064103
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Deletion of the KIT gene is associated with liver metastasis and poor prognosis in patients with gastrointestinal stromal tumor in the stomach.
    Cho S; Kitadai Y; Yoshida S; Tanaka S; Yoshihara M; Yoshida K; Chayama K
    Int J Oncol; 2006 Jun; 28(6):1361-7. PubMed ID: 16685437
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Spectrum of mutations in gastrointestinal stromal tumor patients - a population-based study from Slovakia.
    Minárik G; Plank L; Lasabová Z; Szemes T; Burjanivová T; Szépe P; Buzalková V; Porubský D; Sufliarsky J
    APMIS; 2013 Jun; 121(6):539-48. PubMed ID: 23106360
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Correlation of KIT and platelet-derived growth factor receptor alpha mutations with gene activation and expression profiles in gastrointestinal stromal tumors.
    Kang HJ; Nam SW; Kim H; Rhee H; Kim NG; Kim H; Hyung WJ; Noh SH; Kim JH; Yun CO; Liu ET; Kim H
    Oncogene; 2005 Feb; 24(6):1066-74. PubMed ID: 15690055
    [TBL] [Abstract][Full Text] [Related]  

  • 53. KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study.
    Rossi S; Gasparotto D; Miceli R; Toffolatti L; Gallina G; Scaramel E; Marzotto A; Boscato E; Messerini L; Bearzi I; Mazzoleni G; Capella C; Arrigoni G; Sonzogni A; Sidoni A; Mariani L; Amore P; Gronchi A; Casali PG; Maestro R; Dei Tos AP
    Am J Surg Pathol; 2015 Jul; 39(7):922-30. PubMed ID: 25970686
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High expression of the RNA-binding protein RBPMS2 in gastrointestinal stromal tumors.
    Hapkova I; Skarda J; Rouleau C; Thys A; Notarnicola C; Janikova M; Bernex F; Rypka M; Vanderwinden JM; Faure S; Vesely J; de Santa Barbara P
    Exp Mol Pathol; 2013 Apr; 94(2):314-21. PubMed ID: 23295309
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recurrent and metastatic extragastrointestinal stromal tumors of the mesentery with C-KIT and PDGFRA mutations: a case report.
    Yayu H; Changmao Z; Yijun D; Na L; Tianwen X; Yangbin D
    Cancer Biol Ther; 2020; 21(2):101-107. PubMed ID: 31599195
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity.
    Debiec-Rychter M; Wasag B; Stul M; De Wever I; Van Oosterom A; Hagemeijer A; Sciot R
    J Pathol; 2004 Apr; 202(4):430-8. PubMed ID: 15095270
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of mutational analysis of KIT and PDGFRA in gastrointestinal stromal tumors in a clinical setting.
    Maleddu A; Pantaleo MA; Nannini M; Biasco G
    J Transl Med; 2011 May; 9():75. PubMed ID: 21605429
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Strong PDGFRA positivity is seen in GISTs but not in other intra-abdominal mesenchymal tumors: Immunohistochemical and mutational analyses.
    Peterson MR; Piao Z; Weidner N; Yi ES
    Appl Immunohistochem Mol Morphol; 2006 Dec; 14(4):390-6. PubMed ID: 17122634
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Correlation between mutational status and survival and second cancer risk assessment in patients with gastrointestinal stromal tumors: a population-based study.
    Rubió-Casadevall J; Borràs JL; Carmona-García MC; Ameijide A; Gonzalez-Vidal A; Ortiz MR; Bosch R; Riu F; Parada D; Martí E; Miró J; Sirvent JJ; Galceran J; Marcos-Gragera R
    World J Surg Oncol; 2015 Feb; 13():47. PubMed ID: 25885906
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Detection of KIT and PDGFRA mutations in the plasma of patients with gastrointestinal stromal tumor.
    Kang G; Bae BN; Sohn BS; Pyo JS; Kang GH; Kim KM
    Target Oncol; 2015 Dec; 10(4):597-601. PubMed ID: 25735500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.